GlassScriptPhysician profile
David D Wilt
NPI 1083614739
$90,373.82
in general payments reported to CMS, 2019-2025
75 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19K · 2022: $19K · 2023: $9,144 · 2024: $14K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $18K · Consulting Fee: $3,000 · Travel and Lodging: $2,981 · Education: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,106.25 |
| Food and Beverage | $17,780.26 |
| Consulting Fee | $3,000.00 |
| Travel and Lodging | $2,981.37 |
| Education | $308.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37,728.18 | 2021-2025 | |
| Pfizer INC. | $18,430.19 | 2021-2025 | |
| Allergan, INC. | $4,839.54 | 2021-2022 | |
| Amgen INC. | $4,637.76 | 2021-2025 | Uplizna, Aimovig |
| Teva Pharmaceuticals USA, INC. | $1,979.22 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $1,952.06 | 2021-2025 | Fintepla, Rystiggo, Briviact |
| Janssen Pharmaceuticals, INC | $1,680.79 | 2021-2022 | |
| Biogen, INC. | $1,513.78 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Emd Serono, INC. | $1,115.16 | 2021-2025 | Mavenclad, Mavenclad |
| Neurocrine Biosciences, INC. | $956.46 | 2021-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $910.51 | 2021-2025 | Nuplazid |
| Tg Therapeutics, INC. | $826.49 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $823.68 | 2021-2025 | |
| Argenx US, INC. | $771.93 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $760.92 | 2021-2025 |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $707.36 | 2021-2025 | Ultomiris |
| Sk Life Science, INC. | $619.52 | 2021-2025 | |
| Mdd US Operations, LLC | $590.82 | 2021-2025 | Gocovri, Gocovri, Myobloc |
| Horizon Therapeutics Plc | $586.29 | 2021-2023 | Uplizna |
| Genzyme Corporation | $544.92 | 2021-2025 | |
| Axsome Therapeutics, INC. | $449.51 | 2022-2025 | Sunosi, Symbravo |
| Catalyst Pharmaceuticals, INC. | $393.16 | 2023-2025 | Fycompa |
| Celgene Corporation | $393.05 | 2022-2025 | Zeposia |
| Otsuka America Pharmaceutical, INC. | $370.19 | 2023-2025 | Rexulti, Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $354.46 | 2022 | |
| Genentech USA, INC. | $354.15 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Lilly USA, LLC | $351.08 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $350.93 | 2021-2025 | Hyqvia, Gammagard |
| Alnylam Pharmaceuticals INC. | $350.81 | 2022-2025 | Onpattro |
| Merz Pharmaceuticals, LLC | $342.76 | 2022-2025 | Xeomin, Inbrija |
| Kyowa Kirin, INC. | $307.46 | 2021-2024 | Nourianz |
| Neurelis, INC. | $267.73 | 2024-2025 | Valtoco |
| Octapharma USA, INC. | $234.22 | 2022-2025 | Panzyga |
| Biohaven Pharmaceuticals, INC. | $216.72 | 2021 | |
| Avanir Pharmaceuticals, INC. | $208.51 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $205.27 | 2021-2022 | |
| Aquestive Therapeutics, INC. | $204.39 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $195.87 | 2022-2025 | Purified Cortrophin Gel |
| Tanabe Pharma America, INC. | $178.82 | 2021-2025 | Radicava |
| Upsher-Smith Laboratories LLC | $167.26 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $152.18 | 2021-2024 | Wainua, Evusheld |
| Grifols USA, LLC | $148.04 | 2022-2025 | Gamunex-C |
| Impel Pharmaceuticals INC. | $147.03 | 2023 | Trudhesa |
| Acorda Therapeutics, INC | $143.17 | 2021-2022 | |
| Livanova USA, INC. | $123.91 | 2021-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Supernus Pharmaceuticals, INC. | $123.08 | 2021-2025 | Qelbree |
| Xeris Pharmaceuticals, INC. | $121.09 | 2025 | Keveyis |
| Csl Behring | $120.34 | 2023-2025 | Hizentra |
| Jazz Pharmaceuticals INC. | $117.32 | 2022-2024 | |
| Amneal Pharmaceuticals LLC | $114.74 | 2021-2025 | Crexont, Ongentys 50mg Capsules 30 |
| Scilex Pharmaceuticals INC. | $107.29 | 2021-2025 | Ztlido |
| Sumitomo Pharma America, INC. | $102.31 | 2023 | Aptiom |
| Hospira, INC. | $96.44 | 2022-2023 | |
| Cala Health, INC. | $90.70 | 2025 | Cala Kiq |
| Mallinckrodt Hospital Products INC. | $80.15 | 2021-2025 | Acthar |
| Hikma Pharmaceuticals USA | $72.58 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $69.20 | 2023-2025 | Dojolvi |
| E.R. Squibb & Sons, L.L.C. | $57.06 | 2022-2025 | Zeposia |
| Banner Life Sciences, LLC | $54.14 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $48.46 | 2025 | Lumryz |
| Amylyx Pharmaceuticals, INC. | $46.73 | 2023 | Relyvrio |
| Impel Pharmaceuticals LLC | $42.30 | 2025 | Trudhesa |
| Abbott Laboratories | $38.10 | 2023-2024 | Amplatzer Talisman, Infinity |
| Lundbeck LLC | $36.90 | 2024 | Rexulti |
| Harmony Biosciences LLC | $36.15 | 2022-2024 | |
| Avion Pharmaceuticals | $30.29 | 2022 | |
| Sandoz INC. | $26.16 | 2024 | |
| Zogenix INC. | $24.43 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.07 | 2024 | Caplyta |
| Philips North America LLC | $23.04 | 2024 | (Cm9) Amb Mon & Diag Und |
| Tonix Medicines, INC. | $20.25 | 2025 | Tonmya |
| Adamas Pharmaceuticals, INC. | $19.62 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.54 | 2021 | |
| Vanda Pharmaceuticals INC. | $13.86 | 2025 | Fanapt, Hetlioz |
| Aprecia Pharmaceuticals, LLC | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wilt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.